|My mid year review of GERN|
INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.
GERN (market cap is $0.677B was $0.272B)
Geron is a leading edge biotech developing treatments for blood disorders by managing telomeres. The specific application may suffice to make the company profitable, if the treatment is approved; but the more general application could extend to other cancers and illnesses caused by improper cell death or growth. If proven, that opens the market to treating auto-immune disorders as well as cancers. Some treatments are in variations of Phase Three clinical trials, but approval and profitability can be years away.
Perhaps the better description is that Geron was, rather than is, a leading edge biotech. While their technologies are advanced, their development has taken decades during which competition has developed, the company's earlier suite of technologies has reduced to one, and the company's financial situation continues to rely on limited income.
I continue to hold because the company has made progress, and because selling now does not generate much cash. The fate and fortune of the company will probably be determined within the next few years. I've waited a long time. I can wait some more.
DISCLOSURE LTBH since 1999 and continuing to hold. I might consider buying more, but will probably wait for substantial, quantitative results to be made public - which would spark a spike that might price me out of the sale. Stay tuned.
(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.net )